-
HanchorBio and Henlius Pharmaceutical Enter Strategic Collaboration for Immunotherapies
•
Taiwan-based HanchorBio has entered into a strategic cooperation framework agreement with Shanghai-headquartered Shanghai Henlius Biotech, Inc. (HKG: 2696). The collaboration aims to combine HanchorBio’s expertise in protein engineering modification and its proprietary “Fc based multifunctional innovative biological agent (FBDB)” platform with Henlius Pharma’s fully integrated product development and commercialization capabilities.…
-
HanchorBio’s HCB101 Receives WFDA Approval for Multi-Region Clinical Study
•
Taiwan-based HanchorBio has announced that it has received approval from the Taiwan Food and Drug Administration (WFDA) to conduct a multi-region, multi-center clinical study for its innovative fusion protein, HCB101. HCB101: A Promising Fusion Protein for Cancer TreatmentHCB101 is an engineered SIRP linked to IgG4-Fc α fusion proteins that can…
-
HanchorBio Receives FDA Approval for Multi-Region Clinical Study of HCB101 Fusion Protein
•
Taiwan-based HanchorBio has announced receiving the green light from the US FDA to conduct a multi-region, multi-center clinical study for its innovative fusion protein, HCB101. The non-blind, dose exploration first-in-human trial will be conducted in the US and Taiwan, focusing on assessing the safety, tolerability, pharmacokinetics, and preliminary clinical anti-tumor…
